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See Editorial, pages 1002–1004Background and Aims: There remains uncertainty about the nat- Conclusions: Contrary to current dogma, this study suggests that
ural history of non-alcoholic fatty liver disease (NAFLD). The
spectrum of NAFLD includes non-alcoholic fatty liver (NAFL; ste-
atosis without hepatocellular injury) and steatohepatitis (NASH;
steatosis with hepatocyte ballooning degeneration ± ﬁbrosis).
Our aim was to assess the histological severity of NAFLD in a
cohort with serial biopsy data, and determine factors predicting
progression.
Methods: Patients with two liver biopsies more than a year apart
were identiﬁed. Clinical and laboratory data were collected from
the time of liver biopsy.
Results: 108 patients had serial biopsies (median interval
6.6 years, range 1.3–22.6). 81 (75%) patients had NASH and 27
had NAFL. Overall, 45 (42%) patients had ﬁbrosis progression,
43 (40%) had no change in ﬁbrosis, while 20 (18%) had ﬁbrosis
regression. Importantly, no signiﬁcant difference in the propor-
tion exhibiting ﬁbrosis progression was found between those
with NAFL or NASH at index biopsy (37% vs. 43%, p = 0.65).
Progression to NASH was seen in 44% of patients with baseline
NAFL. Of 10 patients with NAFL who had ﬁbrosis progression, 3
progressed by 1 stage, 5 by 2 stages and 2 by 3 stages; all had
NASH on follow-up biopsy. Of concern, 6 of 27 (22%) patients
with baseline NAFL, reached stage 3 ﬁbrosis at follow-up biopsy.
Among the patients with NAFL, 80% of those having ﬁbrosis pro-
gression were diabetic at the follow-up liver biopsy compared
with 25% of non-progressors (p = 0.005).Journal of Hepatology 20
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is considered the hepa-
tic manifestation of a metabolic syndrome and is currently the
most common cause of liver disease in many developed countries
worldwide [1–3]. Studies suggest that approximately 30% of the
general population have radiological evidence of steatosis and
8% have raised transaminases due to NAFLD, although many go
unrecognised [4–7]. NAFLD is deﬁned as steatosis affecting >5%
of hepatocytes in the absence of excessive signiﬁcant alcohol con-
sumption, other liver disease or the consumption of steatogenic
drugs. The histological spectrum of NAFLD includes non-alcoholic
fatty liver (NAFL; steatosis without hepatocellular injury), steato-
hepatitis (NASH; steatosis with inﬂammation and hepatocyte
ballooning degeneration), ﬁbrosis and ultimately cirrhosis [8].
Those patients who progress to cirrhosis are at risk of potentially
life threatening liver-related complications such as portal hyper-
tension, hepatic failure and hepatocellular carcinoma [9–13].
There remains considerable uncertainty about the natural his-
tory and prognosis of NAFLD. Despite its high prevalence, only a
minority of NAFLD patients progress to signiﬁcant ﬁbrosis or
experience associated morbidity [3]. This variability is in part
due to subtle individual genetic differences that modify response
to environmental factors and lifestyle, and so determine disease
phenotype [14–16]. Few studies, together totalling approxi-
mately 400 patients, have examined the histological evolution
of steatosis, steatohepatitis and ﬁbrosis in NAFLD patients using
paired biopsies [17–26]. In general, it is thought that ﬁbrosis
progression in patients with NAFL is uncommon, whereas NASH
progresses more frequently [18,19,21–25]. However, two small
studies have recently challenged this dogma, suggesting that
NAFL can evolve to NASH with advanced ﬁbrosis, which would
imply that it may not be an entirely benign condition [20,26].
Open access under CC BY-NC-ND license.15 vol. 62 j 1148–1155
JOURNAL OF HEPATOLOGY
The aim of the DELTA study was to assess the change in histolog-
ical severity and evolving natural history of NAFLD using serial
liver biopsies in a histologically characterised patient cohort,
and to determine which clinical factors were predictors of pro-
gressive hepatic ﬁbrosis.Materials and methods
Patients
Patients with 2 or more liver biopsies, taken at least 1-year apart, were identiﬁed
from a sub-specialist tertiary NAFLD clinic at the Freeman Hospital, Newcastle
upon Tyne, UK. Index liver biopsies were performed between 1991 and 2011 as
part of investigation of abnormal liver function tests, or to stage disease severity,
in patients with radiological evidence of NAFLD. Follow-up liver biopsies were
conducted between 2001 and 2013 to assess disease progression or as an entry
requirement for inclusion in a clinical trial. Due to the uncertain natural history
of NAFLD, it was our usual practice to perform a follow-up liver biopsy at 5-yearly
intervals to monitor for disease progression in pre-cirrhotic patients aged <65-
years who failed lifestyle intervention. For patients with >2 liver biopsies, the ﬁrst
and last biopsies were used, unless the patient had participated in a therapeutic
clinical trial where the pre-trial biopsy was used (therefore no patients received
trial medications during the study period). Patients with alternate liver diagnoses
or evidence of coexistent liver disease (haemochromatosis, viral hepatitis, Wil-
son’s disease, alpha-1-antitrypsin deﬁciency or autoimmune liver disease) were
excluded. Patients who consumed more than 30 g of alcohol per day for males
or more than 20 g per day for females prior to the ﬁrst biopsy or during the fol-
low-up period were also excluded. Five patients with type 2 diabetes and NASH
were receiving pioglitazone during the study period, but none received vitamin
E. Fig. 1 summarises study recruitment as a CONSORT ﬂow diagram. Clinical
and laboratory data were collected from the time of liver biopsy. For patients
who had liver biopsies prior to 1999, data was collected retrospectively from
the time of liver biopsy or within 6 months, but data was collected prospectively
since 1999. Relevant clinical details such as gender, age, weight, height and aver-
age current and previous alcohol intake (g/day) were obtained from all patients at
the time of liver biopsy. The body mass index (BMI) was calculated by the for-
mula: weight (kg)/height2 (m2). Patients were identiﬁed as having type 2 diabetes
(T2DM) if they were receiving dietary, oral hypoglycaemic drug or insulin treat-
ment for diabetes, or had fasting blood glucose >7.0 mmol/L or glucose
>11.1 mmol/L following an oral glucose tolerance test. Blood tests taken at the
time of liver biopsy or within 6-months were used to calculate the FIB-4 and
Non-alcoholic fatty liver ﬁbrosis scores (NAFLD ﬁbrosis score) as previously
described [27–29].Histologically characterised
NAFLD cohort (N = 448)
F0-3 fibrosis at index biopsy
(N = 407)
DELTA cohort:
patients with ≥2 biopsies
(N = 108)
F4 fibrosis (cirrhosis) 
at index biopsy (N = 41)
<5-years since index biopsy 
(N = 76)
Age >65 when 5-year 
interval biopsy due (N = 22)
Lost to follow-up (N = 140) 
or dead (N = 17)
Substantial weight loss or 
declined repeat biopsy 
(N = 44)
Fig. 1. DELTA study CONSORT diagram.
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Percutaneous liver biopsies were performed using a Menghini needle or an 18G
BioPince liver biopsy system (Medical Devices Technologies, Gainesville, Florida,
USA). Liver biopsies were all >15 mm in length and were read by an experienced
hepatopathologist (ADB). Histological scoring was performed according to the
NASH Clinical Research Network criteria (NASH CRN) [30]. The NAFLD activity
score (NAS) was graded from 0 to 8 including scores for steatosis (0–3), lobular
inﬂammation (0–3) and hepatocellular ballooning (0–2). Fibrosis was staged from
0 to 4. ‘NASH’ was deﬁned as steatosis with hepatocyte ballooning degeneration
and inﬂammation +/ ﬁbrosis [31]. ‘NAFL’ was deﬁned as steatosis only, or stea-
tosis with mild inﬂammation without hepatocyte ballooning degeneration. ‘Bland
steatosis’ was deﬁned as steatosis, but no hepatocyte ballooning, inﬂammation or
ﬁbrosis. ‘Steatosis and mild inﬂammation’ was deﬁned as steatosis with mild lob-
ular inﬂammation with 6stage 1 ﬁbrosis, but no hepatocyte ballooning. Three
patients with signiﬁcant liver injury (1 patient with steatosis and stage 3 ﬁbrosis
and 2 patients with steatosis, lobular inﬂammation and stage 2 ﬁbrosis) were
classiﬁed as ‘‘NASH’’ despite hepatocyte ballooning degeneration being absent.
In these patients the cause of the signiﬁcant liver injury was believed to be due
to NASH and it is likely that sampling error played a role in the ﬁnding of absence
of hepatocyte ballooning degeneration. The rate of ﬁbrosis was calculated by:
(last biopsy ﬁbrosis stage – ﬁrst biopsy ﬁbrosis stage)/time between biopsies
(years).
Statistical analysis
All statistical analyses were performed using SPSS software version 21.0 (SPSS
Inc, Chicago, USA). Continuous normally distributed variables were represented
as mean ± standard deviation (SD). Categorical and non-normal variables were
summarised as median and range. Chi squared test or Fisher’s exact test were
used to determine the distribution of categorical variables between groups. To
compare the means of normally distributed variables between groups the Stu-
dent’s t test was performed. To determine differences between groups for contin-
uous non-normally distributed variables, medians were compared using the
Mann-Whitney U test. Longitudinal changes in continuous variables were
assessed by paired t test or Wilcoxon rank-sum test. Binary logistic regression
was performed to identify factors associated with progression of ﬁbrosis. Signif-
icant factors on univariate analysis were included in the multivariate analysis.
The diagnostic performance of non-invasive tests was assessed by receiver oper-
ating characteristic (ROC) curves. The area under the ROC (AUROC) was used as an
index to compare the accuracy of tests. The sensitivity and speciﬁcity for relevant
cut-offs were also displayed.Results
As summarised in Fig. 1, from a total of 448 patients with histo-
logically conﬁrmed NAFLD, 108 patients were identiﬁed with at
least 2 liver biopsies, more than 1-year apart, that met the inclu-
sion/exclusion criteria. These patients comprised the DELTA
study cohort that was used in subsequent analyses.
Cohort characteristics at baseline
Patient characteristics are summarised in Table 1. Two-thirds
(71) of the cohort was male. At the time of the index biopsy,
the mean age was 48 ± 12 years and 52 (48%) had T2DM.
Histological assessment determined that one-quarter (n = 27)
of the patients had NAFL, of whom 17 had ‘bland steatosis’ and 10
had ‘steatosis with mild inﬂammation’ but without evidence of
ballooning hepatocyte degeneration. Three-quarters (n = 81) of
the patients had NASH with a median NAS of 4 (range: 1–8).
Table 2 shows a comparison between subjects with NAFL and
NASH at index biopsy. Compared with subjects with NAFL on
index biopsy, patients with NASH were signiﬁcantly older
(p <0.001), more likely to be diabetic (p = 0.004) and had higher
serum IgA levels (p = 0.01), AST/ALT ratio (p = 0.01), FIB-4 scorevol. 62 j 1148–1155 1149
Table 1. Comparison of the clinical and demographic factors at baseline and
follow-up liver biopsy.
Characteristic Baseline Follow up p value
Age (years) 48 ± 12 55 ± 12 <0.001*
Gender (% male) 66% 66% -
BMI (kg/m2) 33.9 ± 5.0 34.9 ± 5.2 0.004*
T2DM 48% 65% <0.001#
ALT (IU/L) 112 ± 80 79 ± 66 <0.001*
AST (IU/L) 73 ± 48 57 ± 35 0.01*
GGT (IU/L) 117 ± 105 148 ± 195 0.11*
Platelets (x109/L) 244 ± 67 230 ± 62 <0.001*
IgA (g/L) 2.88 ± 1.36 3.26 ± 1.50 0.06^
IgG (g/L) 12.7 ± 12.9 10.9 ± 3.1 0.24^
Ferritin 281 ± 536 194 ± 218 0.17*
AST/ALT ratio 0.7 ± 0.27 0.81 ± 0.30 <0.001*
FIB-4 score 1.5 ± 1.0 1.79 ± 1.39 0.036*
NAFLD score -1.49 ± 1.42 -0.77 ± 1.38 <0.001*
NAS 4 (1-8)  4 (1-7) 0.64^
Steatosis 2 (1-3) 2 (1-3)
1 (0-3) 1 (0-3)
Ballooning 1 (0-2) 1 (0-2)
Fibrosis stage 2 (0-3) 2 (0-4) <0.001^
0 23 (21%) 23 (21%)
1 29 (27%) 19 (18%)
2 33 (31%) 19 (18%)
3 23 (21%) 33 (31%)
4 0 (0%) 13 (12%)
Steatosis/NASH 27 (25%)/
81 (75%)
21 (19%)/
87 (81%)
0.14#
Inflammation
⁄Paired t test.
^Wilcoxon signed rank test.
#Chi Square test.
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; GGT, gamma glutamyltransferase; NAS, non-alcoholic fatty liver
disease activity score; T2DM, type 2 diabetes mellitus.
Table 2. Comparison between patients with NAFL and those with NASH at
baseline and follow-up liver biopsies.
Characteristic NAFL 
N = 27
NASH 
n = 83
p value
41 ± 11 50 ± 12 <0.001*
67% 65% 0.91#
32.9 ± 5.2 34.1 ± 4.9 0.33*
21% 56% 0.004#
119 ± 97 109 ± 75 0.64*
64 ± 46 75 ± 49 0.40*
151 ± 113 109 ± 102 0.13*
250 ± 80 243 ± 64 0.67*
11.2 ± 2.1 13.1 ± 14.4 0.57*
2.17 ± 1.02 3.05 ± 1.39 0.01*
0.54 ± 0.17 0.74 ± 0.28 0.01*
0.89 ± 0.42 1.62 ± 1.01 <0.001*
-2.15 ± 1.49 -1.37 ± 1.38 0.07*
2 (1-4) 5 (1-8) <0.001^
Age (years)
Gender (% male)
BMI (kg/m2)
T2DM
ALT (IU/L)
AST (IU/L)
GGT (IU/L)
Platelets (x109/L)
IgG (g/L)
IgA (g/L)
AST/ALT ratio
FIB-4 score
NAFLD score
Baseline NAS
0 (0-1) 2 (0-3) <0.001^
0 19 (70%) 4 (5%)
1 8 (30%) 21 (26%)
2 0 33 (41%)
3 0 23 (28%)
4 0 0
Follow up NAS 3 (1-6) 4 (1-7) 0.001^
0 (0-3) 2 (0-4) <0.001^
0 15 (56%) 8 (10%)
1 4 (15%) 16 (20%)
2 2 (7%) 17 (21%)
3 6 (22%) 27 (33%)
4 0 13 (16%)
Fibrosis progressor 37% 43% 0.65#
Fibrosis rate (stage/yr) 0.067 ± 0.11 0.084 ± 0.29 0.67*
Time between biopsies 8 (1.7-22.6) 6.4 (1.3-18.5) 0.34^
Baseline fibrosis
Follow up fibrosis
⁄Student’s t test.
^Mann-Whitney U test.
#Fisher’s exact test.
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; GGT, gamma glutamyltransferase; NAS, non-alcoholic fatty liver
disease activity score; T2DM,type 2 diabetes mellitus.
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Fig. 2. Relationship between ﬁbrosis stage and simple non-invasive ﬁbrosis
scores. Relationship between stage of ﬁbrosis and (A) the NAFLD ﬁbrosis score,
and (B) the FIB-4 score.
Research Article(p <0.001), NAS (p <0.001) and NASH CRN ﬁbrosis stage
(p <0.001).
Fibrosis stage on index biopsy ranged from 0 to 3 with each of
these ﬁbrosis stages well represented within the cohort. At the
index biopsy stage of ﬁbrosis was signiﬁcantly associated with
the NAS (p <0.001), NAFLD ﬁbrosis score (p = 0.004; Fig. 2A),
FIB-4 score (p <0.001; Fig. 2B), age (p = 0.006), BMI (p = 0.034)
and the presence of diabetes (p <0.001).
Metabolic and histological evolution of disease during follow-up
The median time between the index and follow-up liver biopsy
was 6.6 years (IQR: 3.8–9.0; range: 1.3–22.6 years). 73 (68%) of
the patients had liver biopsies more than 5-years apart. Overall,
at the time of follow-up liver biopsy, patient adiposity measured
as BMI had signiﬁcantly increased (mean 34.9 ± 5.0 vs.
33.9 ± 5.2 kg/m2; p = 0.004). Patients were more likely to have
T2DM (65% vs. 48%, p <0.001) and in general exhibited more
advanced hepatic ﬁbrosis (p <0.001). A detailed comparison of
the clinical characteristics of the cohort at the time of index
and follow-up biopsies is shown in Table 1.
Changes from baseline histological grade (activity of steato-
hepatitis) are shown in Table 3. Of the 81 patients with NASH1150 Journal of Hepatology 2015on index biopsy, 75 (93%) still had NASH at follow-up while 6
had regressed to NAFL. Among the 27 patients with NAFL as base-vol. 62 j 1148–1155
Table 3. Distribution of histological disease activity at index and follow-up
liver biopsies.
Baseline disease 
activity
Follow-up disease activity
Bland 
steatosis
Steatosis 
and mild 
inflammation
NASH Total
Bland steatosis 7 6 4 17
Steatosis and mild 
inflammation
2 0 8 10
NASH 5 1 75 81
Total 14 7 87 108
Numbers in bold indicate progression of disease activity.
JOURNAL OF HEPATOLOGYline, 12 (44%) patients had progressed to NASH at follow-up
biopsy. The principal factor associated with signiﬁcant changes
in NAS between liver biopsies was change in BMI (rs = 0.23,
p = 0.026), with increased BMI potentially conferring an increased
risk of steatohepatitis.
During the interval between biopsies 45 (42%) patients had
progression of ﬁbrosis, 43 (40%) patients had no change in their
ﬁbrosis scores, while 20 (18%) patients had regression of ﬁbrosis.
The distribution of changes in ﬁbrosis stage between baseline and
follow-up is shown in Table 4. Of the patients whose ﬁbrosis pro-
gressed, 26 progressed by 1 stage, 15 by 2 stages and 4 by 3
stages. Overall, the mean rate of ﬁbrosis was 0.08 ± 0.25 stages/
year, increasing to 0.29 ± 0.24 stages/year when only those with
disease progression were considered. For patients who had ﬁbro-
sis regression, 17 patients regressed by 1 stage and 3 patients by
2 stages.
At follow-up liver biopsy 46 (43%) patients had advanced
ﬁbrosis (33 had stage 3 and 10 had cirrhosis (stage 4). These
patients were more likely to have T2DM (89% vs. 47%,
p <0.001), and as expected exhibited signiﬁcantly higher follow-
up NAFLD ﬁbrosis score (p <0.001) and FIB-4 score (p = 0.001)
than patients with less advanced ﬁbrosis (stage 0–2). There was
a signiﬁcant relationship between the change in ﬁbrosis stage
between biopsies and the change in both NAFLD ﬁbrosis score
(rs = 0.24, p = 0.035) and FIB-4 score (rs = 0.24, p = 0.033). The
NAFLD ﬁbrosis score identiﬁed patients with advanced ﬁbrosis
on follow-up liver biopsy with reasonable accuracy (AUROC:
0.83, CI: 0.74–0.92, p <0.001; 91% sensitivity and 46% speciﬁcity
at a score of 1.455, and 28% sensitivity and 98% speciﬁcity at
a score of 0.676), whereas the FIB-4 score had modest accuracy
(AUROC: 0.72, CI: 0.62–82).Table 4. Distribution of histological ﬁbrosis at index and follow-up liver
biopsy.
Baseline 
fibrosis
Follow-up fibrosis stage
Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Total
Stage 0 16 4 1 2 0 23
Stage 1 6 7 3 11 2 29
Stage 2 1 7 11 11 3 33
Stage 3 0 2 4 9 8 23
Stage 4 0 0 0 0 0 0
Total 23 20 19 33 13 108
Numbers in bold indicate ﬁbrosis progression.
Journal of Hepatology 2015Subgroup comparison between ﬁbrosis progressors and non-
progressors
To identify factors that were associated with progressive ﬁbrosis,
patients with histological evidence of increasing ﬁbrosis stage
(progressors) were compared to subjects whose ﬁbrosis remained
stable or regressed (non-progressors). As is shown in Table 5,
although no signiﬁcant difference in histological factors including
NAS (p = 0.19), presence of steatohepatitis (78% vs. 73%, p = 0.65)
or stage of ﬁbrosis (p = 0.90) was evident between groups on
index biopsy, progressors did have a signiﬁcantly lower platelet
count (p = 0.04), a higher AST/ALT ratio (p = 0.04) and higher
FIB-4 score (p = 0.02) at that time. By the time that follow-up
biopsies were performed, progressors continued to exhibit signif-
icantly lower platelet count (p = 0.001), higher AST/ALT ratio
(p = 0.01,) FIB-4 score (p = 0.001). In addition, NAFLD ﬁbrosis
score (p <0.001) was also signiﬁcantly raised compared with
non-progressors. At the time of follow-up biopsy, T2DM was sig-
niﬁcantly more common in patients with progressive ﬁbrosis
(p <0.001) as was histological evidence of steatohepatitis (100%
vs. 67%, p <0.001) and grade of inﬂammation measured by NAS
(p <0.001).
Identiﬁcation of factors at baseline predicting subsequent ﬁbrosis
progression
A multivariate analysis incorporating platelet count, AST/ALT
ratio and FIB-4 score was conducted to identify clinical factors
at the index biopsy that would predict subsequent progression
of ﬁbrosis. The FIB-4 score was the only signiﬁcant baseline factor
that predicted ﬁbrosis progression (OR: 2.1, CI: 1.1–3.9,
p = 0.019). However, the AUROC of the FIB-4 score for predicting
progression of ﬁbrosis was only 0.63 (CI: 0.51–0.76, p = 0.036).
Identiﬁcation of factors at follow-up indicating presence of ﬁbrosis
progression
To identify clinical factors at the time of follow-up liver biopsy
that were indicative of ﬁbrosis progression, a multivariate analy-
sis was conducted incorporating presence of T2DM, platelet
count, GGT, AST/ALT ratio, FIB-4 score, NAFLD ﬁbrosis score.
The presence of T2DM (OR: 6.25, CI: 1.88–20, p = 0.003), and
FIB-4 score (OR: 3.1, CI: 1.4–6.8, p = 0.004) at the time of fol-
low-up liver biopsy were signiﬁcant indicators of presence of
ﬁbrosis progression.
Histological evolution of patients with NAFL on the index liver biopsy
An important and as yet unresolved clinically relevant question is
whether patients without evidence of active steatohepatitis may
subsequently develop progressive liver disease. Among the 27
patients with NAFL on the index biopsy, 12 (44%) had evidence
of NASH on the follow-up liver biopsy over a median follow-up
period of 8 years (range: 1.7–22.6 years; IQR: 6.4–10 years). At
the follow-up liver biopsy, 10 (37%) patients with NAFL had pro-
gression of ﬁbrosis byP1 stage of ﬁbrosis (3 patients by 1 stage,
5 by 2 stages and 2 by 3 stages). The time between biopsies for
the patients who progressed by 3 stages were 15.6 and
19.2 years. For the patients who progressed by 2 stages the inter-
val ranged from 6.4 to 22.6 years. 6 (22%) of the patients with
NAFL at baseline had stage 3 ﬁbrosis at the follow-up biopsy,vol. 62 j 1148–1155 1151
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but none were cirrhotic. There was a trend towards more patients
with steatosis and mild inﬂammation having ﬁbrosis progression
than patients with bland steatosis (60% vs. 24% respectively,
p = 0.07).
Among the patients with NAFL at baseline, 80% of those who
had ﬁbrosis progression were diabetic at the follow-up liver
biopsy (including 5 patients with new onset diabetes), compared
with 25% of the non-progressors (p = 0.005). Patients with NAFL
who had ﬁbrosis progression also had signiﬁcantly higher base-
line NAS (2.5 (2–3) vs. 1 (1–4), p = 0.007) and follow-up NAS
scores (4.5 (3–6) vs. 2 (1–4), p <0.001) compared with those NAFL
patients that did not progress.
Of the 17 patients with bland steatosis at the index biopsy, 4
(24%) patients had ﬁbrosis progression (2 subjects with stage 1
ﬁbrosis after 5 and 15 years, 1 patient with stage 2 ﬁbrosis after
5 years and 1 stage 3 ﬁbrosis after 5 years). In these patients,
baseline and follow-up NAS scores were signiﬁcantly higher in
progressors than non-progressors (2 (2–3) vs. 1(1–2), p = 0.01 and
4.5 (3–5) vs. 2 (1–4), p = 0.006 respectively).Discussion
Due to the high prevalence of NAFLD in the community, deter-
mining the natural history of this disease is vitally important.
The main aim of this study was to assess the histological evolu-
tion of NAFLD in our cohort of patients with sequential liver biop-
sies to look for clinical factors that predict disease progression.
Overall, we found that NAFLD has a very variable natural history
with 42% of patients having progression of ﬁbrosis and 18% hav-
ing regression of ﬁbrosis over a median follow-up period of
6.6 years, which is in agreement with previous studies [17–26].
It is generally believed that few patients with NAFL develop pro-
gressive liver ﬁbrosis, whereas NASH has signiﬁcant ﬁbrogenic
potential and frequently progresses. One of the key ﬁndings of
the present study is that, in contrast to current dogma, 44% of
the patients with NAFL at the index liver biopsy progressed to
NASH and 37% had progression of ﬁbrosis, including 6 (22%)
patients who developed advanced (stage 3) ﬁbrosis.
Interestingly, three other recent studies have also demon-
strated that NAFL has the potential to progress to NASH with
ﬁbrosis. The ﬁrst study was conducted by Wong et al. and pro-
spectively performed liver biopsies at 3 years in a cohort of 52
patients with NAFLD, 29 of whom had a baseline NAS <3. In that
study, ﬁbrosis progression was demonstrated in 28% of patients
with a NAS <3 at baseline, and increases in NAS were seen in
58% [20]. More recently a retrospective French study that
included 25 patients with NAFL found that 16 (64%) of these
patients developed NASH and 6 (24%) progressed to bridging
ﬁbrosis after a mean follow-up period of 3.7 years [26]. A meta-
analysis has now been reported looking at rates of ﬁbrosis pro-
gression in 411 patients with NAFLD who had paired liver biop-
sies [17]. In that study, ﬁbrosis progression was also seen in
patients with NAFL as baseline, although the rates of progression
were slower than in patients who had NASH at index biopsy. This
meta-analysis did have some limitations; in particular, it
included a heterogeneous group of studies that had different his-
tological deﬁnitions of NAFL and NASH, and 7 of the studies
included had less then 25 patients. However, taken together with
our results, these studies clearly demonstrate that NAFL can pro-
gress to NASH with signiﬁcant ﬁbrosis. These ﬁndings suggest1152 Journal of Hepatology 2015that current guidelines on the management of NAFLD [8] should
be revised to indicate that NAFL has the potential to progress.
Although we have demonstrated that ﬁbrosis progression can
occur in patients with NAFL, it remains unknown whether this
will have an impact or liver-related morbidity and mortality,
and large long-term prospective studies are required to answer
this question.
Even in the absence of NASH, lobular inﬂammation has been
identiﬁed as a predictor of ﬁbrosis [22] or progression of ﬁbrosis
[26]. In our cohort of patients with NAFL, some had ‘‘steatosis
with mild inﬂammation’’, so it could be argued that the presence
of inﬂammation in these patients puts them at risk of the ﬁbrosis
progression. However, we also found progression of ﬁbrosis in
patients with bland steatosis on the index biopsy. Interestingly,
in all those patients with bland steatosis who had ﬁbrosis pro-
gression, steatosis evolved to steatohepatitis and the majority
were diabetic or became diabetic at follow-up. This suggests that
rather than being distinct entities, steatosis and steatohepatitis
represent different stages in the evolution of NAFLD, and that
increases in insulin resistance might be a key factor in the pro-
gression from steatosis to steatohepatitis with ﬁbrosis.
One of the aims of the present study was to identify clinical
factors that can identify patients with ﬁbrosis progression. Unfor-
tunately none of the baseline factors assessed in this study has
sufﬁcient accuracy to be useful clinically to predict ﬁbrosis pro-
gression. However, at the follow-up liver biopsy the presence of
diabetes was an independent predictor of ﬁbrosis progression.
T2DM is a well-recognised risk factor for progression of NASH
[23], and has been shown to be an independent risk factor for
mortality in patients with NAFLD [32]. Therefore, targeting
patients with NAFLD and T2DM for regular liver reassessments
to identify subclinical progression seems logical as they are at
highest risk of developing progressive disease.
Identiﬁcation of patients with advanced ﬁbrosis due to NASH
is important so that they can be screened for liver-related com-
plications such as hepatocellular carcinoma or portal hyperten-
sion. Previous studies have shown that simple non-invasive
scores for ﬁbrosis, such as the NAFLD ﬁbrosis score and FIB-4,
are effective in identifying patients with advanced ﬁbrosis in
NAFLD [28,33–36]. In the present study, there was a signiﬁcant
relationship between the change in NAFLD ﬁbrosis score and
change in ﬁbrosis stage, and the NAFLD ﬁbrosis score was quite
effective at identifying patients with advanced ﬁbrosis on the fol-
low-up liver biopsy (AUROC: 0.83). Therefore, until a more accu-
rate non-invasive test is widely available, the NAFLD ﬁbrosis
score might offer a simple score that could be used to monitor
patients, and identify those requiring further investigations to
conﬁrm advanced ﬁbrosis/cirrhosis. Interestingly, a recent study
has shown that the NAFLD ﬁbrosis score is also effective in pre-
dicting liver-related complications and death in patients with
NAFLD [37].
This study does have some weaknesses. Firstly, this was a ret-
rospective study, and therefore there was a potential for selection
bias that might have inﬂuenced the observed rates of progres-
sion/regression. However, due to the uncertain natural history
of NAFLD, it was our usual unit practice to perform follow-up
liver biopsies at approximately 5-year intervals in patients who
had failed lifestyle interventions. Even with the potential selec-
tion bias the ﬁnding that NAFL can evolve to NASH with signiﬁ-
cant ﬁbrosis holds true. Secondly, as with any study using liver
biopsy as a standard, sampling error might have led to miss-diag-vol. 62 j 1148–1155
Table 5. Clinical factors at baseline and follow-up biopsy for all patients and a comparison between patients with ﬁbrosis progression and those without
progression.
Characteristic All patients (n = 108) No progression of fibrosis (n = 63) Progression of fibrosis (n = 45) p value
48 ± 12 47 ± 12 49 ± 13 0.39*
66% 67% 64% 0.81#
33.9 ± 5.0 33.4 ± 4.1 34.5 ± 5.8 0.28*
1.0 ± 3.4 0.92 ± 2.6 1.1 ± 4.2 0.77*
48% 43% 53% 0.30
112 ± 80 113 ± 82 110 ± 77 0.89*
73 ± 48 65 ± 40 84 ± 57 0.06*
117 ± 105 112 ± 91 124 ± 122 0.55*
244 ± 67 255 ± 69 229 ± 60 0.04*
2.88 ± 1.36 2.87 ± 1.48 2.88 ± 1.19 0.96*
12.7 ± 12.9 11.7 ± 2.6 14.2 ± 20 0.36*
281 ± 536 322 ± 700 230 ± 187 0.40*
0.7 ± 0.27 0.65 ± 0.22 0.78 ± 0.32 0.04*
1.5 ± 1.0 1.26 ± 0.57 1.85 ± 1.31 0.02*
-1.49 ± 1.42 -1.71 ± 1.23 -1.18 ± 1.62 0.11*
Results at baseline biopsy
Age (years)
Gender (% male)
BMI (kg/m2)
Change in BMI (kg/m2)
T2DM
ALT (IU/L)
AST (IU/L)
GGT (IU/L)
Platelets (x109/L)
IgA (g/L)
IgG (g/L)
Ferritin
AST/ALT ratio
FIB-4 score
NAFLD score
NAS 4 (1-8) 4 (1-8) 4 (2-7) 0.19^
Steatosis 2 (1-3) 2 (1-3) 2 (1-3) 0.08^
Inflammation 1 (0-3) 1 (0-3) 1 (0-3) 0.89^
Ballooning 1 (0-2) 1 (0-2) 1 (0-2) 0.08^
Fibrosis stage 2 (0-3) 2 (0-3) 1 (0-3) 0.90^
0 23 (21%) 16 (25%) 7 (16%)
1 29 (27%) 13 (21%) 16 (36%)
2 33 (31%) 19 (30%) 14 (31%)
3 23 (21%) 25 (24%) 8 (18%)
4 0 (0%) 0 (0%) 0 (0%)
Steatosis/NASH 27 (25%)/81 (75%) 17 (27%)/46 (73%) 10 (22%)/35 (78%) 0.65#
Results at follow up biopsy
BMI (kg/m2) 34.9 ± 5.2 34.4 ± 4.7 35.6 ± 5.9 0.27*
T2DM 65% 51% 84% <0.001
79 ± 66 82 ± 77 76 ± 48 0.63*
57 ± 35 52 ± 34 63 ± 36 0.13*
148 ± 195 109 ± 143 202 ± 239 0.03*
230 ± 62 248 ± 51 208 ± 69 0.001*
3.26 ± 1.50 2.95 ± 1.32 3.7 ± 1.65 0.05*
10.9 ± 3.1 11.2 ± 3.3 10.5 ± 2.7 0.4*
194 ± 218 199 ± 205 187 ± 237 0.81*
0.81 ± 0.30 0.74 ± 0.29 0.89 ± 0.29 0.01*
1.79 ± 1.39 1.36 ± 0.62 2.33 ± 1.69 0.001*
-0.77 ± 1.38 -1.35 ± 1.08 -0.07 ± 1.40 <0.001*
 4 (1-7) 3 (1-6) 5 (3-7) <0.001
ALT (IU/L)
AST (IU/L)
GGT (IU/L)
Platelets (x109/L)
IgA (g/L)
IgG (g/L)
Ferritin
AST/ALT ratio
FIB-4 score
NAFLD score
NAS
Fibrosis stage 2 (0-4) 1 (0-3) 3 (1-4) <0.001^
0 23 (21%) 23 (37%) 0 (0%)
1 19 (18%) 16 (25%) 4 (9%)
2 19 (18%) 15 (24%) 4 (9%)
3 33 (31%) 9 (14%) 24 (53%)
4 13 (12%) 0 (0%) 13 (29%)
Steatosis/NASH 25 (23%)/83 (77%) 21 (33%)/42 (67%) 0 (0%)/44 (100%) <0.001#
Time between biopsy (yr) 6.7 ±  3.5 7.5 ± 5 0.35
Student’s t test.
^Mann-Whitney U test.
#Fisher’s exact test.
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyltransferase; NAS, non-alcoholic fatty liver disease activity
score; T2DM, type 2 diabetes mellitus.
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nosis of disease activity and ﬁbrosis stage at either biopsy [38].
The potential for sampling error in this study was minimised
by including only patients with biopsies >15 mm. Moreover, with
our sample size, the proportion of patients with upstaging or
downstaging of ﬁbrosis or disease activity should equal out, such
that our conclusions are valid. Thirdly, as this was not a con-
trolled trial the impact of potentially confounding factors such
as glycaemic control or prescribed medications (e.g. anti-hyper-
tensives or anti-diabetic agents) on the natural history of NAFLD
could not be assessed.
In conclusion, this study demonstrates that NAFLD has a var-
iable natural history. Importantly and contrary to current dogma,
we have demonstrated that NAFL has the potential to progress to
NASH with advanced ﬁbrosis, particularly in patients who have or
develop diabetes.Conﬂict of interest
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